Bird & Bird secures a win before the UK High Court for Gilead

Bird & Bird’s London patent team has secured a win before the UK High Court for their client Gilead, a global pharmaceutical company known for its work in the medical fields of virology, oncology and inflammation.

On 21 March 2023, Mr Justice Meade held that two patents owned by the Defendant NuCana were invalid for added matter, lack of plausibility and insufficiency including on the basis of the undue burden involved in making the class of “2-methyl up 2-fluorine down” compounds, such as sofosbuvir, falling within the claims. Sofosbuvir is the key component of Gilead’s new class of anti-viral drugs (Solvaldi, Harvoni, Vosevi and Epclusa) that act as inhibitors of an essential enzyme of the Hepatitis C virus. The compound has achieved blockbuster status, with the capability to effectively cure Hepatitis C on a global scale.

In this judgment, the Judge not only considered plausibility, but also “implausibility”, in view of the upcoming decision of the EPO Enlarged Board of Appeal (G2/21, Sumitomo), which has the potential to change the way patentability is assessed in all areas of technology, and particularly the Life Sciences industry.

Bird & Bird’s team comprised IP partners Patrick Kelleher, Jennifer Jones as well as associates Henry Elliott, Ning-Ning Li, Patrick Brown and Josh Price.

News & Deals

More News & Deals
News Bird & Bird strengthens Polish Energy & Utilities team with new partner hire

Sep 02 2025

Read More
News Bird & Bird boosts regulatory team in Brussels with double partner hire

Sep 01 2025

Read More
News Bird & Bird hires corporate crime, compliance and ESG expert David Schreuders as new partner

Sep 01 2025

Read More
News Bird & Bird recognised in World IP Review (WIPR) Global Trade Secrets Ranking 2025

Aug 27 2025

Read More
Deal Bird & Bird advised on the sale of Irish suspension specialist Timoney Dynamic Solutions Ltd to Kessler & Co

Aug 27 2025

Read More
Deal Bird & Bird advised Clubber TV on a significant investment by leading European media group Mediahuis

Aug 27 2025

Read More